Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project
Clinical Microbiology and Infection · 2025
DOI: 10.1016/j.cmi.2025.01.007 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Microbiology and Infection, 2025. Verfasst von Elisa Moreno-Mellado und 21 weiteren Autor:innen. Beteiligte Einrichtung: Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain; Departamento de Medicina, Univers…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Escherichia coli, Escherichia coli Infections, Fosfomycin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas, European Union, European Regional Development Fund.
Abstract (Originalsprache)
OBJECTIVES: The FOSFOMIC study assessed the clinical and microbiological effectiveness, and safety of intravenous fosfomycin in treating complicated urinary tract infections (cUTIs) caused by Escherichia coli, in comparison with other intravenous antimicrobials. METHODS: A prospective, multinational matched cohorts study involving adults with community-acquired cUTIs and receiving targeted therapy with intravenous fosfomycin or other first-line drugs (beta-lactams or fluoroquinolones) was conducted from November 2019 to May 2023 in ten centres from Spain, Italy, and Türkiye. Matching criteria included type of infection acquisition, Charlson and Pitt scores. Endpoints were clinical and microbiological cure, mortality, recurrence, and adverse effects. Analyses used conditional logistic regression and desirability of outcome ranking (DOOR). RESULTS: Overall, 155 matched pairs were included. Clinical and microbiological cure rates were 65.2% (101/155; 95% CI, 57.4-72.2) and 63.2% (98/155; 95% CI, 55.4-70.4) with fosfomycin and comparators, respectively (adjusted OR, 1.09; 95% CI, 0.68-1.73; p 0.73). Mortality rates were 1.9% (3/155; 95% CI, 0.7-5.5) and 5.8% (9/155; 95% CI, 3.1-10.7), respectively (p 0.11). Recurrence rates were 14.2% (22/155; 95% CI, 9.6-20.6) in the fosfomycin group vs. 10.3% (16/155; 95% CI, 6.1-16.1) (p 0.39). Severe adverse effects occurred in 1.9% (3/155; 95% CI, 0.7-5.5) of patients treated with fosfomycin vs. 0.6% (1/155; 95% CI, 0.0-3.3) in the control group (p 0.62). Non-severe adverse effects were more frequent with fosfomycin, affecting 23.3% (36/155; 95% CI, 17.0-30.7) compared with 7.7% (12/155; 95% CI, 4.1-13.1) in the control group (adjusted OR, 5.36; 95% CI, 2.04-14.1; p < 0.001). In DOOR analysis, fosfomycin demonstrated comparable effectiveness in treating pyelonephritis (probability of better DOOR, 54.0%; 95% CI, 48.5-59.6) and in comparison with ceftriaxone (50.3%; 95% CI, 44.7-55.8), without evidence of inferiority in bacteraemic urinary tract infections (DOOR, 47.3%; 95% CI, 41.7-52.8). DISCUSSION: Fosfomycin is a viable option for treating cUTIs caused by E. coli, allowing for diversification in the treatment of these high-incidence infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain; Departamento de Medicina, Universidad de Sevilla/Instituto de Biomedicina de Sevilla/Centro Superior de…
- Department of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey.
- Departamento de Medicina, Universidad de Sevilla/Instituto de Biomedicina de Sevilla/Centro Superior de Investigaciones Científicas (CSIC), Seville, Spain; Unidad de Enfermedades Infecciosas y Microbiología, Hospital Un…
- Unidad de Enfermedades Infecciosas, Hospital Universitario San Cecilio, Instituto de Investigación Biosanitario de Granada, Granada, Spain.
- Department of Infectious Medicine, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
- Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitario de Granada, Granada, Spain.
Förderung
- Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas
- European Union
- European Regional Development Fund
- Instituto de Salud Carlos III
- Ministerio de Ciencia, Innovación y Universidades
- Ministerio de Ciencia e Innovación
Zitieren
APA
Moreno-Mellado, E., Aslan, A. T., Akova, M., León, E., Merchante, N., Vinuesa, D., Moral-Escudero, E., Sadyrbaeva-Dolgova, S., López-Cárdenas, S., Cano-Yuste, Á., Rinaldi, M., Núñez-Núñez, M., Giannella, M., Sojo-Dorado, J., Antolí-Royo, A. C., Chacón, N., Merino-Bohórquez, V., Portillo, I., Rodríguez-Baño, J., …, & FOSFOMIC team (2025). Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2025.01.007
Vancouver
Moreno-Mellado E, Aslan AT, Akova M, León E, Merchante N, Vinuesa D, et al. Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project. Clinical Microbiology and Infection. 2025. doi:10.1016/j.cmi.2025.01.007
BibTeX
@article{MorenoMellado2025,
author = {Moreno-Mellado, Elisa and Aslan, Abdullah Tarik and Akova, Murat and León, Eva and Merchante, Nicolás and Vinuesa, David and Moral-Escudero, Encarnación and Sadyrbaeva-Dolgova, Svetlana and López-Cárdenas, Salvador and Cano-Yuste, Ángela and Rinaldi, Matteo and Núñez-Núñez, María and Giannella, Maddalena and Sojo-Dorado, Jesús and Antolí-Royo, Ana Cristina and Chacón, Natalia and Merino-Bohórquez, Vicente and Portillo, Inés and Rodríguez-Baño, Jesús and Docobo-Pérez, Fernando and Gutiérrez-Gutiérrez, Belén and FOSFOMIC team, FOSFOMIC team},
title = {Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project},
journal = {Clinical Microbiology and Infection},
year = {2025},
doi = {10.1016/j.cmi.2025.01.007}
}
EUVIMED